<DOC>
	<DOCNO>NCT02300844</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate safety , tolerability pharmacokinetics single dos NNC0174-0833 normal weight , overweight obese otherwise healthy male subject .</brief_summary>
	<brief_title>Investigation Safety , Tolerability Pharmacokinetics Single Doses NNC0174-0833 Normal Weight , Overweight Obese But Otherwise Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Normal weight , Overweight obese ( Body Mass Index [ BMI ] ) equal 20.0 35.0 kg/m^2 otherwise healthy men Age equal 22 64 year time signing informed consent History , presence , cancer , diabetes clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder include sleep apnoea , judge investigator Subjects history , presence , disease associate impaired calcium homeostasis and/or increase bone turnover ( e.g . PagetÂ´s disease , osteoporosis ) Male subject reproductive age use highly effective physical barrier method contraception ( sexual abstinence , condom spermicidal foam/gel/film/cream ) combine method Pearl Index less 1 % nonpregnant partner ( ) ( implant , injectables , combine oral contraceptive , hormonal intrauterine device diaphragm+spermicide , surgical sterilisation postmenopausal ) and/or intend donate sperm period start Visit 2 3 month follow administration investigational medicinal product</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>